tegoprazan
Selected indexed studies
- Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. (Br J Clin Pharmacol, 2022) [PMID:35146797]
- Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. (Aliment Pharmacol Ther, 2019) [PMID:30843245]
- Tegoprazan: a novel, highly selective, and potent potassium-competitive acid blocker (P-CAB). (Eur J Clin Pharmacol, 2025) [PMID:40442337]
_Worker-drafted node — pending editorial review._
Connections
tegoprazan is a side effect of
Sources
- Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. (2022) pubmed
- Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. (2019) pubmed
- Tegoprazan: a novel, highly selective, and potent potassium-competitive acid blocker (P-CAB). (2025) pubmed
- Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China. (2024) pubmed
- Tegoprazan-Containing Versus Proton Pump Inhibitor-Containing Therapy for First-Line Eradication of Helicobacter pylori: A Meta-Analysis of Randomized Controlled Trials. (2025) pubmed
- Tegoprazan vs. proton pump inhibitors for erosive esophagitis: a superior alternative or just another option? A systematic review and meta-analysis of randomized controlled trials. (2025) pubmed
- Tegoprazan as First- and Second-Line Therapy for Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. (2025) pubmed
- Tegoprazan Versus Proton Pump Inhibitors for Erosive Esophagitis: A Meta-Analysis of Noninferiority Randomized Controlled Trials. (2025) pubmed
- Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Helicobacter pylori Eradication. (2024) pubmed
- The Effect of Tegoprazan on the Treatment of Endoscopic Resection-Induced Artificial Ulcers: A Multicenter, Randomized, Active-Controlled Study. (2024) pubmed